---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-008849"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:13:34.587078+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Hookipa Q1 net loss $18.0M; cash rises to $141.8M on Gilead deal

## Summary
- Cash, equivalents and restricted cash $141.8M (Dec 2021: $66.9M) from Gilead collaboration and follow-on financing.
- Revenue $1.4M vs $5.3M Q1 2021; $19M in milestone/initiation fees deferred for future recognition.
- R&D expenses $16.6M (down from $20.2M); net loss $18.0M vs $17.2M in prior-year quarter.
- Gilead HIV program advanced: $4M milestone, $15M initiation fee, $35M equity commitment; up to $237M milestones plus royalties.
- HB-200 Phase 1 data due mid-2022; Phase 2 combo with pembrolizumab data in 2H 2022; prostate cancer IND expected Q3 2022.

## SEC filing metadata
- accession: 0001558370-22-008849
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837022008849/0001558370-22-008849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837022008849/hook-20220516x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-008849
- JSON: https://secwatch.observer/filing/0001558370-22-008849.json
- Plain text: https://secwatch.observer/filing/0001558370-22-008849.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.